Loading…

Mechanical Thrombectomy with the Novel NeVa M1 Stent Retriever: Do the Drop Zones Represent a Risk or a Benefit?

The NeVa M1 thrombectomy device is a novel hybrid-cell stent retriever with multifunctional zones for optimized retrieval of resistant clots located in the M1 segment of the middle cerebral artery. The objective was to evaluate the safety and efficacy of the NeVa in a “real-life” setting. Twenty-nin...

Full description

Saved in:
Bibliographic Details
Published in:World neurosurgery 2021-04, Vol.148, p.e121-e129
Main Authors: Borggrefe, Jan, Goertz, Lukas, Abdullayev, Nuran, Hokamp, Nils Große, Kowoll, Christina Maria, Onur, Özgür, Kabbasch, Christoph, Schlamann, Marc
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c356t-c1bec6f4a723b73f1c51e7e1372baedf1df853da53e5392f99bb81ab9da331143
cites cdi_FETCH-LOGICAL-c356t-c1bec6f4a723b73f1c51e7e1372baedf1df853da53e5392f99bb81ab9da331143
container_end_page e129
container_issue
container_start_page e121
container_title World neurosurgery
container_volume 148
creator Borggrefe, Jan
Goertz, Lukas
Abdullayev, Nuran
Hokamp, Nils Große
Kowoll, Christina Maria
Onur, Özgür
Kabbasch, Christoph
Schlamann, Marc
description The NeVa M1 thrombectomy device is a novel hybrid-cell stent retriever with multifunctional zones for optimized retrieval of resistant clots located in the M1 segment of the middle cerebral artery. The objective was to evaluate the safety and efficacy of the NeVa in a “real-life” setting. Twenty-nine consecutive patients (median age: 77 years) treated with the NeVa M1 for acute ischemic stroke of the M1 segement were retrospectively reviewed. First-pass and final modified thrombolysis in cerebral infarction (mTICI) scores, device-related complications, symptomatic intracranial hemorrhage, and 90-day modified Rankin scale (mRS) scores are reported. Primary outcome parameters were first-pass mTICI 2b-3 reperfusion and mRS 0–2 at 90 days. Median National Institutes of Health Stroke Scale scores decreased from 16 to 12 after treatment. mTICI 2b-3 reperfusion rates were 55% after the first pass, 79% after 1–2 passes, and 100% after the final pass. mTICI 2c-3 was obtained in 48% after the first pass, 62% after 1–2 passes, and 72% after the final pass. Rescue treatment was performed in 4 patients (14%). Device-related complications included 1 asymptomatic caroticocavernous fistula, 1 asymptomatic M2 dissection, and 1 symptomatic intracranial hemorrhage. The procedure-related vasospasm rate was 48%. A 90-day mRS of 0–2 was achieved by 31%. The NeVa M1 provides a high first-pass complete reperfusion rate with an adequate safety profile. To retrieve resistant clots, the stent design exerts high mechanical traction forces, which may trigger vasospasm and vessel wall damage. Large, comparative studies are warranted to draw a definite conclusion on this device.
doi_str_mv 10.1016/j.wneu.2020.12.075
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2473405041</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1878875020326425</els_id><sourcerecordid>2473405041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-c1bec6f4a723b73f1c51e7e1372baedf1df853da53e5392f99bb81ab9da331143</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EolXpH-CAfOSyi8cTrxOEhKDlS2qLVAoHLpbjTLRekjjY3q367_GypUd88cjzzCvPw9hzEEsQsHq1Wd5OtF1KIcuDXAqtHrFjqHW9qPWqefxQK3HETlPaiHIQqlrjU3aEiKpREo_ZfElubSfv7MBv1jGMLbkcxjt-6_Oa5zXxq7CjgV_RD8svgX_LNGV-TTl62lF8zc_DX-o8hpn_DBOl0pwjpT1m-bVPv3iIpXpPE_U-v33GnvR2SHR6f5-w7x8_3Jx9Xlx8_fTl7N3FwqFa5YWD8pFVX1ktsdXYg1NAmgC1bC11PXR9rbCzCklhI_umadsabNt0FhGgwhP28pA7x_B7Symb0SdHw2AnCttkZKWxEkpUUFB5QF0MKUXqzRz9aOOdAWH2ss3G7GWbvWwD0hTZZejFff62Hal7GPmntgBvDgCVLXeeoknO0-So87E4Nl3w_8v_AwSrkAk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2473405041</pqid></control><display><type>article</type><title>Mechanical Thrombectomy with the Novel NeVa M1 Stent Retriever: Do the Drop Zones Represent a Risk or a Benefit?</title><source>ScienceDirect Journals</source><creator>Borggrefe, Jan ; Goertz, Lukas ; Abdullayev, Nuran ; Hokamp, Nils Große ; Kowoll, Christina Maria ; Onur, Özgür ; Kabbasch, Christoph ; Schlamann, Marc</creator><creatorcontrib>Borggrefe, Jan ; Goertz, Lukas ; Abdullayev, Nuran ; Hokamp, Nils Große ; Kowoll, Christina Maria ; Onur, Özgür ; Kabbasch, Christoph ; Schlamann, Marc</creatorcontrib><description>The NeVa M1 thrombectomy device is a novel hybrid-cell stent retriever with multifunctional zones for optimized retrieval of resistant clots located in the M1 segment of the middle cerebral artery. The objective was to evaluate the safety and efficacy of the NeVa in a “real-life” setting. Twenty-nine consecutive patients (median age: 77 years) treated with the NeVa M1 for acute ischemic stroke of the M1 segement were retrospectively reviewed. First-pass and final modified thrombolysis in cerebral infarction (mTICI) scores, device-related complications, symptomatic intracranial hemorrhage, and 90-day modified Rankin scale (mRS) scores are reported. Primary outcome parameters were first-pass mTICI 2b-3 reperfusion and mRS 0–2 at 90 days. Median National Institutes of Health Stroke Scale scores decreased from 16 to 12 after treatment. mTICI 2b-3 reperfusion rates were 55% after the first pass, 79% after 1–2 passes, and 100% after the final pass. mTICI 2c-3 was obtained in 48% after the first pass, 62% after 1–2 passes, and 72% after the final pass. Rescue treatment was performed in 4 patients (14%). Device-related complications included 1 asymptomatic caroticocavernous fistula, 1 asymptomatic M2 dissection, and 1 symptomatic intracranial hemorrhage. The procedure-related vasospasm rate was 48%. A 90-day mRS of 0–2 was achieved by 31%. The NeVa M1 provides a high first-pass complete reperfusion rate with an adequate safety profile. To retrieve resistant clots, the stent design exerts high mechanical traction forces, which may trigger vasospasm and vessel wall damage. Large, comparative studies are warranted to draw a definite conclusion on this device.</description><identifier>ISSN: 1878-8750</identifier><identifier>EISSN: 1878-8769</identifier><identifier>DOI: 10.1016/j.wneu.2020.12.075</identifier><identifier>PMID: 33359523</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>First-pass reperfusion ; Large vessel occlusion ; Stroke ; TICI ; Vasospasm</subject><ispartof>World neurosurgery, 2021-04, Vol.148, p.e121-e129</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-c1bec6f4a723b73f1c51e7e1372baedf1df853da53e5392f99bb81ab9da331143</citedby><cites>FETCH-LOGICAL-c356t-c1bec6f4a723b73f1c51e7e1372baedf1df853da53e5392f99bb81ab9da331143</cites><orcidid>0000-0003-3712-2258</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33359523$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Borggrefe, Jan</creatorcontrib><creatorcontrib>Goertz, Lukas</creatorcontrib><creatorcontrib>Abdullayev, Nuran</creatorcontrib><creatorcontrib>Hokamp, Nils Große</creatorcontrib><creatorcontrib>Kowoll, Christina Maria</creatorcontrib><creatorcontrib>Onur, Özgür</creatorcontrib><creatorcontrib>Kabbasch, Christoph</creatorcontrib><creatorcontrib>Schlamann, Marc</creatorcontrib><title>Mechanical Thrombectomy with the Novel NeVa M1 Stent Retriever: Do the Drop Zones Represent a Risk or a Benefit?</title><title>World neurosurgery</title><addtitle>World Neurosurg</addtitle><description>The NeVa M1 thrombectomy device is a novel hybrid-cell stent retriever with multifunctional zones for optimized retrieval of resistant clots located in the M1 segment of the middle cerebral artery. The objective was to evaluate the safety and efficacy of the NeVa in a “real-life” setting. Twenty-nine consecutive patients (median age: 77 years) treated with the NeVa M1 for acute ischemic stroke of the M1 segement were retrospectively reviewed. First-pass and final modified thrombolysis in cerebral infarction (mTICI) scores, device-related complications, symptomatic intracranial hemorrhage, and 90-day modified Rankin scale (mRS) scores are reported. Primary outcome parameters were first-pass mTICI 2b-3 reperfusion and mRS 0–2 at 90 days. Median National Institutes of Health Stroke Scale scores decreased from 16 to 12 after treatment. mTICI 2b-3 reperfusion rates were 55% after the first pass, 79% after 1–2 passes, and 100% after the final pass. mTICI 2c-3 was obtained in 48% after the first pass, 62% after 1–2 passes, and 72% after the final pass. Rescue treatment was performed in 4 patients (14%). Device-related complications included 1 asymptomatic caroticocavernous fistula, 1 asymptomatic M2 dissection, and 1 symptomatic intracranial hemorrhage. The procedure-related vasospasm rate was 48%. A 90-day mRS of 0–2 was achieved by 31%. The NeVa M1 provides a high first-pass complete reperfusion rate with an adequate safety profile. To retrieve resistant clots, the stent design exerts high mechanical traction forces, which may trigger vasospasm and vessel wall damage. Large, comparative studies are warranted to draw a definite conclusion on this device.</description><subject>First-pass reperfusion</subject><subject>Large vessel occlusion</subject><subject>Stroke</subject><subject>TICI</subject><subject>Vasospasm</subject><issn>1878-8750</issn><issn>1878-8769</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kE1v1DAQhi0EolXpH-CAfOSyi8cTrxOEhKDlS2qLVAoHLpbjTLRekjjY3q367_GypUd88cjzzCvPw9hzEEsQsHq1Wd5OtF1KIcuDXAqtHrFjqHW9qPWqefxQK3HETlPaiHIQqlrjU3aEiKpREo_ZfElubSfv7MBv1jGMLbkcxjt-6_Oa5zXxq7CjgV_RD8svgX_LNGV-TTl62lF8zc_DX-o8hpn_DBOl0pwjpT1m-bVPv3iIpXpPE_U-v33GnvR2SHR6f5-w7x8_3Jx9Xlx8_fTl7N3FwqFa5YWD8pFVX1ktsdXYg1NAmgC1bC11PXR9rbCzCklhI_umadsabNt0FhGgwhP28pA7x_B7Symb0SdHw2AnCttkZKWxEkpUUFB5QF0MKUXqzRz9aOOdAWH2ss3G7GWbvWwD0hTZZejFff62Hal7GPmntgBvDgCVLXeeoknO0-So87E4Nl3w_8v_AwSrkAk</recordid><startdate>202104</startdate><enddate>202104</enddate><creator>Borggrefe, Jan</creator><creator>Goertz, Lukas</creator><creator>Abdullayev, Nuran</creator><creator>Hokamp, Nils Große</creator><creator>Kowoll, Christina Maria</creator><creator>Onur, Özgür</creator><creator>Kabbasch, Christoph</creator><creator>Schlamann, Marc</creator><general>Elsevier Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-3712-2258</orcidid></search><sort><creationdate>202104</creationdate><title>Mechanical Thrombectomy with the Novel NeVa M1 Stent Retriever: Do the Drop Zones Represent a Risk or a Benefit?</title><author>Borggrefe, Jan ; Goertz, Lukas ; Abdullayev, Nuran ; Hokamp, Nils Große ; Kowoll, Christina Maria ; Onur, Özgür ; Kabbasch, Christoph ; Schlamann, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-c1bec6f4a723b73f1c51e7e1372baedf1df853da53e5392f99bb81ab9da331143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>First-pass reperfusion</topic><topic>Large vessel occlusion</topic><topic>Stroke</topic><topic>TICI</topic><topic>Vasospasm</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borggrefe, Jan</creatorcontrib><creatorcontrib>Goertz, Lukas</creatorcontrib><creatorcontrib>Abdullayev, Nuran</creatorcontrib><creatorcontrib>Hokamp, Nils Große</creatorcontrib><creatorcontrib>Kowoll, Christina Maria</creatorcontrib><creatorcontrib>Onur, Özgür</creatorcontrib><creatorcontrib>Kabbasch, Christoph</creatorcontrib><creatorcontrib>Schlamann, Marc</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>World neurosurgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borggrefe, Jan</au><au>Goertz, Lukas</au><au>Abdullayev, Nuran</au><au>Hokamp, Nils Große</au><au>Kowoll, Christina Maria</au><au>Onur, Özgür</au><au>Kabbasch, Christoph</au><au>Schlamann, Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanical Thrombectomy with the Novel NeVa M1 Stent Retriever: Do the Drop Zones Represent a Risk or a Benefit?</atitle><jtitle>World neurosurgery</jtitle><addtitle>World Neurosurg</addtitle><date>2021-04</date><risdate>2021</risdate><volume>148</volume><spage>e121</spage><epage>e129</epage><pages>e121-e129</pages><issn>1878-8750</issn><eissn>1878-8769</eissn><abstract>The NeVa M1 thrombectomy device is a novel hybrid-cell stent retriever with multifunctional zones for optimized retrieval of resistant clots located in the M1 segment of the middle cerebral artery. The objective was to evaluate the safety and efficacy of the NeVa in a “real-life” setting. Twenty-nine consecutive patients (median age: 77 years) treated with the NeVa M1 for acute ischemic stroke of the M1 segement were retrospectively reviewed. First-pass and final modified thrombolysis in cerebral infarction (mTICI) scores, device-related complications, symptomatic intracranial hemorrhage, and 90-day modified Rankin scale (mRS) scores are reported. Primary outcome parameters were first-pass mTICI 2b-3 reperfusion and mRS 0–2 at 90 days. Median National Institutes of Health Stroke Scale scores decreased from 16 to 12 after treatment. mTICI 2b-3 reperfusion rates were 55% after the first pass, 79% after 1–2 passes, and 100% after the final pass. mTICI 2c-3 was obtained in 48% after the first pass, 62% after 1–2 passes, and 72% after the final pass. Rescue treatment was performed in 4 patients (14%). Device-related complications included 1 asymptomatic caroticocavernous fistula, 1 asymptomatic M2 dissection, and 1 symptomatic intracranial hemorrhage. The procedure-related vasospasm rate was 48%. A 90-day mRS of 0–2 was achieved by 31%. The NeVa M1 provides a high first-pass complete reperfusion rate with an adequate safety profile. To retrieve resistant clots, the stent design exerts high mechanical traction forces, which may trigger vasospasm and vessel wall damage. Large, comparative studies are warranted to draw a definite conclusion on this device.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>33359523</pmid><doi>10.1016/j.wneu.2020.12.075</doi><orcidid>https://orcid.org/0000-0003-3712-2258</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 1878-8750
ispartof World neurosurgery, 2021-04, Vol.148, p.e121-e129
issn 1878-8750
1878-8769
language eng
recordid cdi_proquest_miscellaneous_2473405041
source ScienceDirect Journals
subjects First-pass reperfusion
Large vessel occlusion
Stroke
TICI
Vasospasm
title Mechanical Thrombectomy with the Novel NeVa M1 Stent Retriever: Do the Drop Zones Represent a Risk or a Benefit?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T04%3A06%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanical%20Thrombectomy%20with%20the%20Novel%20NeVa%20M1%20Stent%20Retriever:%20Do%20the%20Drop%20Zones%20Represent%20a%20Risk%20or%20a%20Benefit?&rft.jtitle=World%20neurosurgery&rft.au=Borggrefe,%20Jan&rft.date=2021-04&rft.volume=148&rft.spage=e121&rft.epage=e129&rft.pages=e121-e129&rft.issn=1878-8750&rft.eissn=1878-8769&rft_id=info:doi/10.1016/j.wneu.2020.12.075&rft_dat=%3Cproquest_cross%3E2473405041%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c356t-c1bec6f4a723b73f1c51e7e1372baedf1df853da53e5392f99bb81ab9da331143%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2473405041&rft_id=info:pmid/33359523&rfr_iscdi=true